Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.
Shah VN, Agesen RM, Bardtrum L, Christiansen E, Snaith J, Greenfield JR. Shah VN, et al. Among authors: bardtrum l. J Diabetes Sci Technol. 2024 Dec 24:19322968241305647. doi: 10.1177/19322968241305647. Online ahead of print. J Diabetes Sci Technol. 2024. PMID: 39717993 Free PMC article.
Combining SNAC and C10 in oral tablet formulations for gastric peptide delivery: A preclinical and clinical study.
Niu Z, La Zara D, Blaabjerg L, Pessi J, Raptis K, Toftlev A, Sauter M, Christophersen P, Bardonnet PL, Andersson V, Wu JX, Brandt M, Fan L, Wang Z, Hubálek F, Wahlund PO, Norrman M, Breusova K, Hjaltason MS, Mortensen NR, Bardtrum L, Nissen B, Naelapää K, Sassene PJ. Niu Z, et al. Among authors: bardtrum l. J Control Release. 2024 Dec 10;378:92-102. doi: 10.1016/j.jconrel.2024.11.078. Online ahead of print. J Control Release. 2024. PMID: 39645088 Free article.
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Dejgaard TF, von Scholten BJ, Christiansen E, Kreiner FF, Bardtrum L, von Herrath M, Mathieu C, Madsbad S; ADJUNCT ONE and ADJUNCT TWO Investigators. Dejgaard TF, et al. Among authors: bardtrum l. Diabetes Obes Metab. 2021 Dec;23(12):2752-2762. doi: 10.1111/dom.14532. Epub 2021 Sep 28. Diabetes Obes Metab. 2021. PMID: 34463425 Free PMC article. Clinical Trial.
Commentary to "Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec" by Kawaguchi et al. Diabetes Therapy 2019.
Pieber TR, Bardtrum L, Isendahl J, Wagner L, Nishimura R. Pieber TR, et al. Among authors: bardtrum l. Diabetes Ther. 2020 Feb;11(2):561-567. doi: 10.1007/s13300-019-00755-3. Epub 2020 Jan 10. Diabetes Ther. 2020. PMID: 31925723 Free PMC article. No abstract available.
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
Sesti G, Bardtrum L, Dagdelen S, Halladin N, Haluzík M, Őrsy P, Rodríguez M, Aroda VR. Sesti G, et al. Among authors: bardtrum l. Diabetes Obes Metab. 2020 May;22(5):873-878. doi: 10.1111/dom.13957. Epub 2020 Jan 29. Diabetes Obes Metab. 2020. PMID: 31903724 Free PMC article. Clinical Trial.
17 results